Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC
Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.
Brian Henick Columbia University Herbert Irving Comprehensive Cancer Center Experimental Therapeutics Translational Research Aerodigestive Cancers Medical Oncology
Source: onclive.com